Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight

What Was Tested

The paper reports a study of Orforglipron (Foundayo, non-peptide), published as a randomized controlled trial.

To evaluate the bioequivalence of orally administered orforglipron tablets and capsules in participants with obesity or overweight who were otherwise healthy.

A prespecified mixed scaling approach was applied to evaluate bioequivalence.

Who Took Part

The study group was 429 adults.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Orforglipron (Foundayo, non-peptide) and who got the comparison, which limits bias.

Nothing was hidden in this open-label Orforglipron (Foundayo, non-peptide) study: the adults and staff both knew the treatment.

Running at several centres spread the Orforglipron (Foundayo, non-peptide) study over different clinics and patient groups.

The primary endpoint was steady-state area under the concentration-time curve from 0 to 24 h (AUC0-24,ss) and steady-state maximum observed drug concentration (C max,ss).

Safety and tolerability of the tablets and capsules were also assessed.

What Was Measured

PubMed files the paper under topics including Anti-Obesity Agents, Area Under Curve, Capsules, Obesity, Overweight, Tablets and Therapeutic Equivalency.

The authors tagged it with the keywords GLP‐1, antiobesity drug and obesity therapy.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Orforglipron (Foundayo, non-peptide) in 429 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.